The TMPRSS2 inhibitor, Camostat, has been reported to correct some of the metabolic abnormalities present in rats with diabetes and obesity (109), however, it is not clear that these effects were specific to inhibition of TMPRSS2. This evidence concerns the gene TMPRSS2 and obesity due to melanocortin 4 receptor deficiency.